Targeted Anticoagulation for Atrial Fibrillation Guided by Continuous Rhythm Assessment With an Insertable Cardiac Monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study

Chronic anticoagulation is recommended for patients with AF and additional stroke risk factors, even during long periods of sinus rhythm. Continuous rhythm assessment with an insertable cardiac monitor (ICM) and use of rapid onset novel oral anticoagulants (NOACs) allow for targeted anticoagulation only around an AF episode, potentially reducing bleeding complications without compromising stroke risk.

[1]  Giuseppe Ciconte,et al.  The Role of Implantable Cardiac Monitors in Atrial Fibrillation Management. , 2017, Journal of atrial fibrillation.

[2]  R. Passman.  Monitoring for AF: Identifying the Burden of Atrial Fibrillation and Assessing Post-Ablation , 2017, The Journal of innovations in cardiac rhythm management.

[3]  D. Singer,et al.  Atrial Fibrillation Burden and Short-Term Risk of Stroke: Case-Crossover Analysis of Continuously Recorded Heart Rhythm From Cardiac Electronic Implanted Devices , 2015, Circulation. Arrhythmia and electrophysiology.

[4]  G. Hindricks,et al.  Cardiogenic Stroke Despite Low CHA2DS2‐VASc Score: Assessing Stroke risk by Left Atrial Appendage Anatomy (ASK LAA) , 2015, Journal of cardiovascular electrophysiology.

[5]  G. Lip,et al.  Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. , 2015, European heart journal.

[6]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[7]  D. Lin,et al.  Risk of Stroke or Transient Ischemic Attack After Atrial Fibrillation Ablation with Oral Anticoagulant Use Guided by ECG Monitoring and Pulse Assessment , 2014, Journal of cardiovascular electrophysiology.

[8]  A. Capucci,et al.  Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events , 2014, Circulation.

[9]  M. Turakhia,et al.  Association of CHADS2, CHA2DS2-VASc, and R2CHADS2 scores with left atrial dysfunction in patients with coronary heart disease (from the Heart and Soul study). , 2014, The American journal of cardiology.

[10]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[11]  D. Atar,et al.  Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .

[12]  C. Morillo,et al.  Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. , 2013, JAMA internal medicine.

[13]  G. Lip,et al.  Inflammation in atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[14]  Jinkwon Kim,et al.  Stroke mechanism in patients with non‐valvular atrial fibrillation according to the CHADS2 and CHA2DS2‐VASc scores , 2012, European journal of neurology.

[15]  A. Capucci,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[16]  S. Sack,et al.  Detection of atrial high-rate events by continuous Home Monitoring: clinical significance in the heart failure–cardiac resynchronization therapy population , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[17]  Christopher E Hilker,et al.  Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. , 2011, Heart rhythm.

[18]  N. Cogan,et al.  Interobserver agreement in ABCD scoring between non-stroke specialists and vascular neurologists following suspected TIA is only fair , 2011, Journal of Neurology.

[19]  Gerhard Hindricks,et al.  Performance of a New Leadless Implantable Cardiac Monitor in Detecting and Quantifying Atrial Fibrillation Results of the XPECT Trial , 2010, Circulation. Arrhythmia and electrophysiology.

[20]  S. Themistoclakis,et al.  The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. , 2010, Journal of the American College of Cardiology.

[21]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[22]  Dongfeng Qi,et al.  The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study , 2009, Circulation. Arrhythmia and electrophysiology.

[23]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[24]  Massimo Santini,et al.  Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. , 2005, Journal of the American College of Cardiology.

[25]  E. Kaufman,et al.  Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study , 2005 .

[26]  S. Saksena,et al.  Relationship between atrial tachyarrhythmias and symptoms. , 2005, Heart rhythm.

[27]  A. Kadish,et al.  Course of Intraatrial Thrombi Resolution Using Transesophageal Echocardiography , 2003, Echocardiography.

[28]  M. Turakhia,et al.  Association of CHADS 2 , CHA 2 DS 2 -VASc, and R 2 CHADS 2 Scores With Left Atrial Dysfunction in Patients With Coronary Heart Disease (from the Heart and Soul Study) , 2014 .

[29]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[30]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.